Adding a new Alzheimer's disease platform to its portfolio, Athenagen Inc. agreed to merge with Zapaq Inc., a 5-year-old company focused on beta-secretase inhibitors. (BioWorld Today)

Two months after receiving FDA approval for Dacogen to treat myelodysplastic syndromes, MGI Pharma Inc. licensed rights to the drug outside North America to Cilag GmbH. (BioWorld Today)

The pancreatic cancer community received another blow on Wednesday when Therion Biologics Corp. announced that Panvac-VF failed to meet its primary endpoint of improving overall survival compared with palliative chemotherapy. (BioWorld Today)

Entering its first major global partnership, privately held Affymax Inc. turned to its Japanese partner Takeda Pharmaceutical Co. Inc. to grant the rest-of-the-world rights to its anemia drug, Hematide. (BioWorld Today)